Christopher Leamon

Company: Fusion Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

225Ac-Targeted Therapy: Advancing Antibody & Small Molecule-Based Agents into the Clinic 9:00 am

• Uncover the power of targeted radiotherapy over targeted chemotherapy • Why is 225Ac an attractive radioisotope for targeted therapy? • Discuss the advantages and challenges of antibody-based radiotherapyRead more

day: Conference Day 2

Panel Discussion: Comparing Antibodies, Peptides & Small Molecules as Targeting Molecules to Improve Stability & Accuracy of Your TRP 9:30 am

• Highlighting the advantages of antibodies, peptides and small molecules • Understanding the difference each makes to the final TRP • Analysing which molecule to choose depending on your targetRead more

day: Conference Day 2